europe-istock-468428817
slavemotion / iStockphoto.com
25 April 2018Big Pharma

AG opines on ‘thorny issue’ in Truvada SPC clash

Advocate General Melchior Wathelet has advised the Court of Justice of the European Union (CJEU) on a case involving a supplementary protection certificate (SPC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
28 June 2018   Switzerland’s highest court held that new supplementary protection certificates for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.

More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
28 June 2018   Switzerland’s highest court held that new supplementary protection certificates for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.

More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
28 June 2018   Switzerland’s highest court held that new supplementary protection certificates for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.